ArticleBMC chemistry2025
Novel spectrophotometric methods for concurrent assessment of duloxetine and avanafil in their binary mixture using derivative spectroscopy: greenness-blueness evaluation.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antidepressant drugs, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are known to induce sexual dysfunction as a side effect. Duloxetine (DLX) and Avanafil (AVN) are simultaneously determined in their pure state and laboratory-prepared mixtures by two novel, environmentally friendly spectrophotometric methods. The first method was based on second order derivatives while the second method is based on first derivative dual-wavelength. In method I, the linearity range was found to be 0.5-12 µg/mL and 1-12 µg/mL with limit of detection 0.15 µg/mL and 0.27 µg/mL for DLX and AVN, respectively. In method II, the linearity range was found to be 1-10 µg/mL for both drugs with limit of detection 0.18 µg/mL and 0.21 µg/mL for DLX and AVN, respectively. The validation of these approaches meets the International Council for Harmonization's (ICH) standards. Furthermore, three current ecological tools namely the Eco-Scale, GAPI, and AGREE were used to evaluate the proposed method's greenness. The sustainability characteristics of the proposed method were also assessed using the Blue Applicability Grade Index (BAGI), a recently developed metric for assessing the practicality (blueness) of procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.